THROUGH UNIVERSITY RESEARCH AND DEVELOPMENT
With a scientific team at Western University, CanaQuest Medical Corp has created a few CREATIVE patentable product formulations. Our research and product development focuses on health products utilizing cannabis isolates and botanical compounds, including algae oils (pharmaceutical grade).
To learn more about our value proposition and the benefits of our commercial-ready products, view the full presentation on the Investors page or by clicking the thumbnail graphic further down.
CanaQuest Store
Visit our online store to pre-register or subscribe for information.
Investor Presentation
PRODUCT FORMULATIONS
A critical mass of clinical evidence regarding the efficacy of medical cannabis is refuting political, scientific, and other skeptics, and opening minds hardened by decades of anti-cannabis propaganda. Our goal is to develop better alternative treatments to traditional pharmaceuticals for people struggling with a variety of health challenges.
CQ1 (Mentabinol®)
Commercial Ready
(THC + formula)
Supports mental health: Anxiety, depression, and schizophrenia.
CQ2 (Mentanine®)
Commercial Ready
(Omega 3 + formula)
Supports mental health: Anxiety, depression, PTSD and addiction.
CQ3 (Mentanine – pain®)
Commercial Ready
(Omega 3 + formula)
To support endocannabinoid system health: Inflammation and pain.
CQ4 (Menata…®)
Coming soon
(More details to be released)
To support mental health: Alzheimer’s.
FOCUS AREAS
Anxiety
Addiction
Depression
Schizophrenia
PTSD
Pain
IN THE NEWS
CanaQuest Announces Mentabinol® – A Scientific Discovery, as Published in the Journal of Neuroscience
TORONTO, Dec. 03, 2020 -- CANAQUEST MEDICAL CORP (OTC Markets: “CANQF”) (the "Company" or “CanaQuest”), a Life Science/Pharmaceutical Company developing health products utilizing cannabinoid molecules and other botanical compounds (pharmaceutical grade), today announced that The Journal of [...]
CanaQuest Medical Corp Secures Approval For Listing On The Ocmx™, An Online Investor And Financial Connection Portal
TORONTO – September 17, 2020 − CANAQUEST MEDICAL CORP (OTC Markets: “CANQF”) (the "Company" or “CanaQuest”), a Life Science/Pharmaceutical Company developing health products utilizing cannabinoid molecules and other botanical compounds (pharmaceutical grade), today announced that it has [...]
CanaQuest Medical Corp Files Provisional Patent For Mentanine® – Omega-3 & Pure Cannabidiol (“CBD”) Formulation Boosting Mental Health Efficacy While Minimizing CBD Dosage
TORONTO – July 14, 2020 − CANAQUEST MEDICAL CORP (OTC Markets: “CANQF”) (the "Company" or “CanaQuest”), a company developing unique health products and nutraceuticals utilizing cannabis/hemp molecules and botanical compounds, has filed a Provisional Cannabidiol/Omega-3 Patent, trade [...]